Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.
Interested individuals can be referred by physicians, or by family or friends. Individuals are informed that the purpose of this study is to collect outcome data following early detection testing based upon our criteria for elevated risk. Consent is obtained by any of the co-investigators. Consent is obtained for the primary PCEDP, and also obtained to allow for data to be used by our Cancer Program. We have a weekly review of all calls made and of all enrollments. We have a monthly meeting to review all proceeding regarding the study. Our IRB routinely reviews the proceedings of the study Our institution has a monthly Clinical research Committee meeting.
Study Type
OBSERVATIONAL
Enrollment
100
White Plains Hospital
White Plains, New York, United States
Premalignant or malignant pancreatic conditions found with alternating EUS and MRI testing.
Number of Participants with Premalignant or Malignant Pancreatic Conditions, as a Measure of Safety and Efficacy
Time frame: 5 years
Clinical outcomes which occur as a result of this Protocol
Prospective collection and reporting of any malignant conditions which occur as a result of this Protocol, including from surgery, or other testing.
Time frame: 5 years
Complications of any interventions as a result of this Protocol
Prospective collection and reporting of any complications that may be associated with early detection testing, including hospitalization, disability, and death.
Time frame: 5 years
Non-Pancreatic cancers diagnosed while on this protocol
Prospective collection and reporting of non-pancreatic cancers detected during this Protocol, including pancreatic cysts.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.